28Nov 2024
MRAs: Expanding Horizons in Heart Failure Management

MRAs: Expanding Horizons in Heart Failure Management

Mineralocorticoid receptor antagonists (MRAs) have significantly advanced the treatment of heart failure (HF). Spironolactone has long improved outcomes in patients with severe HF with reduced ejection fraction (HFrEF), while eplerenone expanded these benefits to milder HFrEF and post-myocardial infarction HF. More recently, finerenone demonstrated efficacy in HF with preserved ejection fraction (HFpEF), extending its benefits previously observed in diabetes and albuminuric chronic kidney disease populations. Concerns over hyperkalemia have historically limited MRA use, but improved education on predicting, preventing, and managing this risk could broaden their application. Ongoing trials continue to explore both steroidal and nonsteroidal MRAs in diverse HF populations, underscoring their evolving role in HF management.

  • #cardiology

Like

Save

Share